Anixa Biosciences, Inc. (ANIX)
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
$111.58M
Dr. Amit Kumar Ph.D.
4.00
San Jose, CA
Oct 07, 1983
-8.89
$-0.39
0.61
11.31
-7,923.72%
-8.92
-0.33
5.06
709.60
11.31
-53.96%
-52.41%
Similar stocks (13)
Arcellx, Inc.
ACLX
Immunome, Inc.
IMNM
Rezolute, Inc.
RZLT
Acrivon Therapeutics, Inc. Common Stock
ACRV
Annovis Bio, Inc.
ANVS
INmune Bio, Inc.
INMB
PMV Pharmaceuticals, Inc.
PMVP
Aerovate Therapeutics, Inc.
AVTE
Anebulo Pharmaceuticals, Inc.
ANEB
AN2 Therapeutics, Inc.
ANTX
Cue Biopharma, Inc.
CUE
IN8bio, Inc.
INAB
TFF Pharmaceuticals, Inc.
TFFP
ETF Exposure (12)
iShares Micro-Cap ETF
IWC
0.02714%
Dimensional U.S. Core Equity 2 ETF
DFAC
5.0350000000000004e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (13)
Arcellx, Inc.
ACLX
Immunome, Inc.
IMNM
Rezolute, Inc.
RZLT
Acrivon Therapeutics, Inc. Common Stock
ACRV
Annovis Bio, Inc.
ANVS
INmune Bio, Inc.
INMB
PMV Pharmaceuticals, Inc.
PMVP
Aerovate Therapeutics, Inc.
AVTE
Anebulo Pharmaceuticals, Inc.
ANEB
AN2 Therapeutics, Inc.
ANTX
Cue Biopharma, Inc.
CUE
IN8bio, Inc.
INAB
TFF Pharmaceuticals, Inc.
TFFP
ETF Exposure (12)
iShares Micro-Cap ETF
IWC
0.02714%
Dimensional U.S. Core Equity 2 ETF
DFAC
5.0350000000000004e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%